Monopar Therapeutics (NASDAQ:MNPR) Issues Quarterly Earnings Results, Misses Expectations By $0.13 EPS

Monopar Therapeutics (NASDAQ:MNPR) posted its quarterly earnings data on Wednesday. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.13), FiscalAI reports.

Monopar Therapeutics Stock Down 0.1%

Shares of MNPR traded down $0.16 during mid-day trading on Wednesday, reaching $114.30. The company’s stock had a trading volume of 184,271 shares, compared to its average volume of 221,278. The company has a market cap of $765.70 million, a price-to-earnings ratio of -60.16 and a beta of 1.47. Monopar Therapeutics has a 1 year low of $29.18 and a 1 year high of $124.82. The business has a fifty day moving average of $92.93 and a 200 day moving average of $70.68.

Wall Street Analyst Weigh In

A number of analysts recently commented on MNPR shares. Wall Street Zen upgraded shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. UBS Group set a $125.00 price target on Monopar Therapeutics in a report on Thursday, July 23rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, July 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. Finally, BTIG Research lifted their target price on Monopar Therapeutics from $104.00 to $117.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Three investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $112.08.

Hedge Funds Weigh In On Monopar Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Invesco Ltd. purchased a new stake in shares of Monopar Therapeutics in the fourth quarter worth approximately $219,000. ADAR1 Capital Management LLC increased its stake in Monopar Therapeutics by 79.9% in the 4th quarter. ADAR1 Capital Management LLC now owns 233,908 shares of the company’s stock valued at $15,274,000 after buying an additional 103,909 shares during the period. Virtus Investment Advisers LLC purchased a new stake in Monopar Therapeutics in the 4th quarter worth approximately $233,000. Millennium Management LLC lifted its position in Monopar Therapeutics by 945.5% in the 4th quarter. Millennium Management LLC now owns 76,674 shares of the company’s stock worth $5,007,000 after buying an additional 69,340 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of Monopar Therapeutics by 2.3% during the 4th quarter. Janus Henderson Group PLC now owns 1,317,410 shares of the company’s stock valued at $85,908,000 after buying an additional 30,042 shares during the period. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.